Cargando…

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

The protein p53 protects the organism against carcinogenic events by the induction of cell cycle arrest and DNA repair program upon DNA damage. Virtually all cancers inactivate p53 either by mutations/deletions of the TP53 gene or by boosting negative regulation of p53 activity. The overexpression o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skalniak, Lukasz, Kocik, Justyna, Polak, Justyna, Skalniak, Anna, Rak, Monika, Wolnicka-Glubisz, Agnieszka, Holak, Tad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266412/ https://www.ncbi.nlm.nih.gov/pubmed/30352966 http://dx.doi.org/10.3390/cancers10110396

Ejemplares similares

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
por: Kocik, Justyna, et al.
Publicado: (2019)

MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
por: Khurana, Arushi, et al.
Publicado: (2019)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Surmiak, Ewa, et al.
Publicado: (2021)

CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
por: Musielak, Bogdan, et al.
Publicado: (2019)

Human and mouse PD-L1: similar molecular structure, but different druggability profiles
por: Magiera-Mularz, Katarzyna, et al.
Publicado: (2020)

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies
por: Rodriguez, Ismael, et al.
Publicado: (2023)

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma
por: Lakoma, A, et al.
Publicado: (2015)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2015)

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
por: Shaabani, Shabnam, et al.
Publicado: (2022)

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Riboflavin and Its Derivates as Potential Photosensitizers in the Photodynamic Treatment of Skin Cancers
por: Insińska-Rak, Małgorzata, et al.
Publicado: (2023)

Dual Action of Curcumin as an Anti- and Pro-Oxidant from a Biophysical Perspective
por: Wolnicka-Glubisz, Agnieszka, et al.
Publicado: (2023)

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2016)

Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells
por: Natarajan, Umamaheswari, et al.
Publicado: (2018)

MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κB
por: Skalniak, Lukasz, et al.
Publicado: (2014)

Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors
por: Ważyńska, Marta A., et al.
Publicado: (2023)

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2017)

Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G(0)/G(1) Arrest by Inhibiting Deubiquitinase USP2a
por: Magiera, Katarzyna, et al.
Publicado: (2017)

Proteasome inhibitor MG-132 induces MCPIP1 expression
por: Skalniak, Lukasz, et al.
Publicado: (2013)

miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia
por: Zanjirband, Maryam, et al.
Publicado: (2023)

HGF/SF Increases Number of Skin Melanocytes but Does Not Alter Quality or Quantity of Follicular Melanogenesis
por: Wolnicka-Glubisz, Agnieszka, et al.
Publicado: (2013)

Review article: The meristem in indeterminate root nodules of Faboideae
por: Łotocka, Barbara, et al.
Publicado: (2013)

Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21(WAF1/CIP1) and p27(KIP1) in Cancer Cells
por: Natarajan, Umamaheswari, et al.
Publicado: (2019)

Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients
por: So, W. Venus, et al.
Publicado: (2018)

Deciphering the Functional Role of RIPK4 in Melanoma
por: Madej, Ewelina, et al.
Publicado: (2021)

Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
por: Zauli, Giorgio, et al.
Publicado: (2020)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia
por: Johansson, Kimberly B., et al.
Publicado: (2023)

Contribution of a Novel B3GLCT Variant to Peters Plus Syndrome Discovered by a Combination of Next-Generation Sequencing and Automated Text Mining
por: Totoń-Żurańska, Justyna, et al.
Publicado: (2019)

Germacranolides from Carpesium divaricatum: Some New Data on Cytotoxic and Anti-Inflammatory Activity
por: Kłeczek, Natalia, et al.
Publicado: (2021)

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
por: Lehmann, Christian, et al.
Publicado: (2016)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

Rapid Decrease of CD16 (FcγRIII) Expression on Heat-Shocked Neutrophils and Their Recognition by Macrophages
por: Bzowska, Małgorzata, et al.
Publicado: (2011)

Vemurafenib and Dabrafenib Downregulates RIPK4 Level
por: Madej, Ewelina, et al.
Publicado: (2023)

Artificial Macrocycles as Potent p53–MDM2 Inhibitors
por: Estrada-Ortiz, Natalia, et al.
Publicado: (2017)

Early Recognition of the PCL/Fibrous Carbon Nanocomposites Interaction with Osteoblast-like Cells by Raman Spectroscopy
por: Wesełucha-Birczyńska, Aleksandra, et al.
Publicado: (2021)

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
por: Italiano, Antoine, et al.
Publicado: (2021)

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
por: Mascarenhas, John, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fet4msrdfh6qmbjcm6766v5mnm